Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Accumulated Expenses (2016 - 2025)

CytomX Therapeutics' Other Accumulated Expenses history spans 12 years, with the latest figure at $142000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 71.02% year-over-year to $142000.0; the TTM value through Dec 2025 reached $142000.0, down 71.02%, while the annual FY2025 figure was $142000.0, 71.02% down from the prior year.
  • Other Accumulated Expenses reached $142000.0 in Q4 2025 per CTMX's latest filing, down from $341000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $943000.0 in Q1 2022 to a low of $63000.0 in Q1 2025.
  • Average Other Accumulated Expenses over 5 years is $390450.0, with a median of $327500.0 recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: surged 601.52% in 2021, then crashed 86.15% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $713000.0 in 2021, then plummeted by 63.39% to $261000.0 in 2022, then rose by 20.31% to $314000.0 in 2023, then soared by 56.05% to $490000.0 in 2024, then tumbled by 71.02% to $142000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Other Accumulated Expenses are $142000.0 (Q4 2025), $341000.0 (Q3 2025), and $111000.0 (Q2 2025).